Surrey Heartlands

Joint Formulary & PAD

Pizotifen - Migraine (prevention)

You are here : Home > Formulary Search > Pizotifen - Migraine (prevention)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
SPC
Restrictions / Comments :
Documents :
 
Safety Information
Pizotifen safety advice - Apr 2024

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Pizotifen
Indication :
Migraine (prevention)
Group Name :
Keywords :
cluster headaches, migraine prevention, migraine prophylaxis
Brand Names Include :
Sanomigran
Important Information :
Review existing patients and consider alternative. Discontinuation of pizotifen requires gradual withdrawal.
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Migraine (prevention)
Supporting Documents :
1

Other Indications

Below are listed other indications that Pizotifen is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Migraine (prevention).

Committee Recommendations (3)

04 Jun 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartland Integrated Care System Area Prescribing Committee agreed a PAD narrative message for patients currently on treatment with pizotifen for migraine prophylaxis in primary care, as follows:

Long term use of pizotifen (like most migraine prophylactic medication) is rarely indicated and withdrawal should normally be attempted after 9 months. If, after 2-months of withdrawal, migraine frequency increases to warrant prophylactic medication again options to consider in discussion with the patient would be:
• Alternative prophylactic medication as per the Surrey Headache Pathway
• Re-start pizotifen only if there were no previous major side effects of low mood, weight gain and cognitive symptoms.

10 Apr 24 - Surrey Heartlands Medicines Safety Committee (MSC)

The Medicine Safety Committee has developed "Pizotifen safety advice" for healthcare professionals to consider when prescribing and monitoring patients on pizotifen

01 Jul 15 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
This drug has been agreed as appropriate for initiation in Primary Care and/or continued in Primary Care following a recommendation from specialists in other health care sectors. Following consideration by the PCN, it has been assigned a GREEN traffic light status